Wyeth Accepts Redux Settlement Amendment
This article was originally published in The Pink Sheet Daily
Wyeth has agreed to an amendment to the Redux class action settlement that covers claimants with less serious medical conditions, the company said Jan. 10
You may also be interested in...
Wyeth will decide the week of Jan. 10 whether to accept an amendment to the Redux class action settlement that covers claimants with less serious medical conditions, CEO Robert Essner said
The number of Redux patients that opt into the "seventh amendment" to the diet drug litigation settlement will determine whether Wyeth has adequate legal reserves. The amendment creates a $1.275 bil. fund for fen/phen patients with less serious medical conditions.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.